论文信息 - High rate of virologic response after discontinuation of nucleos(t)ide analogues in Caucasian chronic hepatitis B patients. - 字舞流文

High rate of virologic response after discontinuation of nucleos(t)ide analogues in Caucasian chronic hepatitis B patients.

D. Abdurakhmanov | E. Ibragimov | S. Panevkina

[1] T. Berg,et al. Views on stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B. , 2020, Antiviral research.

[2] G. Papatheodoridis,et al. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B , 2020, Cells.

[3] H. Van Vlierberghe,et al. Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion , 2019, Viruses.

[4] H. Van Vlierberghe,et al. Sustained off‐treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced HBeAg seroconversion , 2019, Journal of viral hepatitis.

[5] E. Rigopoulou,et al. DARING-B: Discontinuation of Effective Entecavir or Tenofovir Disoproxil Fumarate Long-Term Therapy before HBsAg Loss in Non-Cirrhotic HBeAg-Negative Chronic Hepatitis B , 2018, Antiviral therapy.

[6] T. Berg,et al. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. , 2017, Journal of hepatology.

[7] D. Vassilopoulos,et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. , 2012, Gastroenterology.